Payer Q1 Comeback Meets Oz's 50-State Medicaid Audit and a Renewed Prior Auth Crackdown

The week of April 20-26, 2026 delivered the clearest evidence yet that the great managed-care reset of 2025 is starting to pay off—and the clearest evidence that Washington is not done extracting concessions from the industry. Within a 96-hour window, UnitedHealth Group, Elevance Health, and Molina Healthcare reported first-quarter results that all beat consensus and led to raised full-year guidance, while CMS Administrator Mehmet Oz dispatched letters to all 50 governors ordering a sweeping Medicaid provider revalidation, a bipartisan group of lawmakers reintroduced a more aggressive Medicare Advantage prior authorization reform bill, and the FDA and CMS unveiled a joint pathway designed to compress Medicare device coverage timelines from years to days. For employers, brokers, and the carriers underwriting their plans, the takeaway from the week is not so much that the worst is over—Tim Noel, the new chief executive of UnitedHealthcare, was emphatic that it is not—but that margin recovery and regulatory pressure are now arriving on the same calendar.

The earnings turnaround that arrived in three acts

UnitedHealth Group set the tone on Tuesday, April 21, when it reported $111.7 billion in first-quarter revenue, $9.0 billion in earnings from operations, and adjusted earnings per share of $7.23 against a Wall Street consensus closer to $6.61. The medical care ratio—the single most-watched number in managed care this cycle—came in at 83.9 percent, an improvement of roughly 90 basis points from the 84.8 percent reported a year earlier. Stephen Hemsley, who returned to the CEO role last May after the company's annus horribilis, used the call to argue that the company's turnaround is running ahead of plan, and the board responded by raising 2026 adjusted EPS guidance from "greater than $17.75" to "greater than $18.25." The market rewarded the performance with a roughly 9 percent rally in UnitedHealth shares and a sympathy gain in Humana, on the read that Medicare Advantage cost trends had finally stopped deteriorating.

But the more consequential commentary came from Tim Noel, the UnitedHealthcare segment CEO who took over the insurance business this year. Asked whether the favorable medical loss ratio signaled an inflection, Noel pushed back. "We continue to see the utilization patterns continuing with high, elevated levels that we experienced in 2025," he told analysts, adding that the company's 2026 plan filings assumed roughly a 10 percent pricing increase against a 7 to 8 percent Medicare Advantage trend. The favorable Q1 print, in other words, reflects pricing finally catching up to demand—not demand abating. To make the math work, UnitedHealthcare is intentionally shedding members; the segment ended Q1 with 7.555 million Medicare Advantage enrollees, down 965,000 from the 8.445 million on the books at year-end 2025, a willing exit from money-losing geographies and benefit designs that Noel framed as a "deliberate trade-off on membership growth, particularly in Medicare and commercial markets."

Elevance Health followed on Wednesday, April 22, with operating revenue of $49.5 billion, $1.8 billion of net income, and 45.4 million members—up roughly 186,000 from year-end 2025. The headline number was a 19.2 percent decline in net income, but Elevance's medical loss ratio of 86.8 percent was better than analysts feared given the carrier's heavier Medicaid exposure, and the company raised its full-year EPS guide to at least $26.75 from $25.50. Carelon, the company's services arm, grew 7.9 percent year-over-year to $18 billion of revenue, validating Elevance's bet that the path to durable margin lies in vertical integration rather than premium growth. Elevance executives also flagged a continuing migration of marketplace members down-market into bronze plans as enhanced premium tax credits expired, a pattern carriers across the country are watching with concern as it tends to correlate with adverse selection.

Molina Healthcare, the smallest of the publicly traded Medicaid pure-plays, closed the cluster on Thursday, April 23, with $10.2 billion in premium revenue, adjusted EPS of $2.35 against a $2.17 consensus, and a consolidated medical care ratio of 91.1 percent. GAAP net income collapsed to $14 million from $298 million a year earlier on the back of a $93 million impairment tied to Molina's planned 2027 exit from its Medicare Advantage Part D business—a write-off the company telegraphed earlier this year and that Wall Street treated as a one-time clean-up. The shares rose more than 5 percent in pre-market trading. Molina reaffirmed full-year guidance of approximately $42 billion in premium revenue and at least $5 of adjusted EPS, and Centene, which reports next week, is widely expected to extend the trend. HCA Healthcare's Friday morning earnings were the lone discordant note: the hospital giant grew revenue 4.3 percent to $19.1 billion but missed EPS estimates by eight cents at $7.15, a reminder that the cost trend punishing payers is now flowing into providers' wage and supply lines.

Oz tells 50 governors to start over on Medicaid provider files

The earnings narrative collided on Thursday, April 23 with a regulatory directive that may end up being the most operationally disruptive policy action of the spring. CMS Administrator Mehmet Oz sent a letter to every governor in the country and to every state Medicaid director, demanding a "swift revalidation" of Medicaid providers operating in what the agency describes as "high-risk areas of waste, fraud, abuse, and corruption." Governors were given 10 business days—until May 7—to confirm whether their state will participate and on what timetable. State Medicaid directors must then submit a comprehensive two-year revalidation strategy within 30 days. CMS left the definition of "high-risk" largely to states, but signaled that any provider lacking a National Provider Identifier and any provider not screened in the previous 12 months should be at the front of the queue.

The directive lands at a particularly awkward moment for managed Medicaid carriers. Centene, Molina, Elevance, and UnitedHealthcare's community plan together cover the bulk of risk-based Medicaid lives, and their network operations teams have spent the past three years navigating the unwinding of pandemic-era continuous enrollment, a wave of state rate adjustments, and the early implementation work tied to last year's One Big Beautiful Bill Act. Layering a federally-mandated provider re-screen on top of those efforts is not, in itself, a coverage threat, but it places significant administrative load on the same MCOs that are already battling cost trend. Georgetown's Center for Children and Families noted that previous revalidation cycles have produced meaningful network attrition simply because providers fail to respond in time, not because they are actually fraudulent—a dynamic that could collide with state network adequacy standards. CMS has framed the initiative as both a fraud measure and a precursor to broader Medicaid integrity work; it followed Oz's earlier preview of the policy at Politico's Health Care Summit on April 22.

A bipartisan revival for prior authorization reform

Also on April 23, a bipartisan group of House lawmakers reintroduced the Medicare Advantage Improvement Act of 2026, the latest iteration of a years-long effort to put statutory teeth behind CMS's existing prior authorization rules. The bill mirrors but goes beyond the agency's 2024 final rule: it would require Medicare Advantage plans to render standard prior authorization decisions within 72 hours and expedited decisions within 24 hours; cap any extensions at 7 days; require real-time, automated approvals integrated with electronic health records; force plans to publish prior authorization data, including determination times; and bind MA plans to traditional Medicare's medical-necessity standards rather than allowing carriers to apply more restrictive criteria. The bill also creates a compliance-scoring regime that would clip MA plans' Medicare payments by up to 2 percent for poor performers. The Medical Group Management Association, AHA, and a coalition of provider groups endorsed the package within hours, and the Medicare Rights Center released new prior authorization data on the same day arguing that publicly available denial rates remain too opaque to police.

The political setup is more interesting than usual. Senate Majority Leader John Thune signaled earlier in the week that the next reconciliation vehicle—Senate Concurrent Resolution 33, which the upper chamber passed on April 22—will be confined to homeland security and will not carry Medicare or Medicaid policy. That removes the most plausible fast track for the prior authorization legislation but also removes the most plausible vehicle for the cuts that progressives feared. Combined with HHS Secretary Robert F. Kennedy Jr.'s testimony before four committees during the week defending a proposed $15.8 billion (12.5 percent) HHS budget cut, the result is a Washington in which the executive branch is moving aggressively on enforcement and pricing transparency while Congress works the edges on prior authorization, PBM transparency (the House Education and Workforce Committee held its "Profits Over Patients: The PBM Business Model Under Scrutiny" hearing on April 22), and TrumpRx-related deductibles legislation introduced earlier in the week to require direct-to-consumer drug prices to count toward private insurance out-of-pocket maximums.

RAPID, FDA, and a faster on-ramp for digital medicine

The third major regulatory action of the week was a joint announcement on April 23 from the FDA and CMS introducing the Regulatory Alignment for Predictable and Immediate Device, or RAPID, Coverage Pathway. Under RAPID, when a Class II or Class III breakthrough device receives FDA market authorization, CMS will issue a proposed national coverage determination on the same day. For technology developers and the venture investors who underwrite them, this is the first concrete fix for the so-called "valley of death" between FDA clearance and Medicare reimbursement, a gap that has historically delayed access to breakthrough devices by 18 to 36 months. The first wave of RAPID-eligible classifications, released the same week, included a sleep apnea testing device that uses mandibular movement, a Setmelanotide eligibility gene-variant detection system, an Alzheimer's disease pathology assessment test, and a digital therapeutic for amblyopia—a deliberate mix of diagnostics, genomics, and software-as-medical-device intended to signal that RAPID is a digital-medicine play, not just a hardware play.

A few key items employers and brokers will want to keep in mind as the policy environment shifts this quarter:

• Medicaid revalidation timing: governors must respond to CMS by May 7, 2026, and state directors must submit two-year strategies within 30 days—expect short-term network adequacy concerns even before any actual fraud is identified.
• Prior authorization compliance: CMS's existing 72-hour standard / 7-day expedited rule already takes effect this year; the MAIA bill would tighten that to 72-hour standard and 24-hour expedited and add 2 percent payment penalties.
• Medicare Advantage cost trends: UnitedHealth priced 2026 plans at roughly 10 percent against a 7-8 percent trend assumption, and is intentionally shedding ~1 million MA lives to restore margin—commercial brokers should expect MA shopping volume to spike during 2027 AEP.

What the week told us about the operating environment

Threaded through the earnings prints, the regulatory directives, and the Capitol Hill activity is a single underlying theme: the cost-trend wave that battered managed care in 2024 and 2025 is finally being absorbed by the rating actions taken last year, but the political constituency for "fixing" managed care has only grown. The Bloomberg feature on April 22 detailing how Claimable, a $10-million-Cuban-backed AI startup, has reversed thousands of denied health insurance claims by sending machine-generated appeals letters to insurers, executives, politicians, and journalists is its own data point about consumer sentiment: even as the largest carriers report the cleanest medical loss ratios they have produced in two years, the public's appetite for adversarial appeals technology continues to grow.

For employers preparing 2027 renewals, the implication is that the relief implied by the Q1 prints is real but partial. Pricing is catching up to trend, but trend is not abating; carriers are choosing margin over membership; the federal government is layering new compliance work onto Medicaid plans at the same time it is tightening Medicare Advantage prior authorization; and the marketplace is on track to absorb major member shifts as enhanced premium tax credits remain expired. Mercer's most recent projection of a 6.5 percent total health benefit cost increase per employee in 2026—the highest jump since 2010—still appears intact, and the share of large employers planning explicit cost-cutting changes to their 2026 plan designs has climbed to 59 percent from 48 percent the year prior. The earnings recovery is welcome news for shareholders. The plan sponsors paying the premiums underneath those earnings are still very much waiting for theirs.

Sources:

• UnitedHealth Group Reports First Quarter 2026 Results
• UnitedHealth tops quarterly estimates, hikes profit outlook (CNBC)
• Elevance Health Reports First Quarter 2026 Results
• Elevance Health raises 2026 outlook (Fierce Healthcare)
• Molina Healthcare Reports First Quarter 2026 Results
• HCA Healthcare Reports First Quarter 2026 Results
• Oz gives states 30 days to plan for Medicaid provider revalidation
• Governors and State Medicaid Directors Get a New Assignment from Dr. Oz (Georgetown CCF)
• Medicare Advantage Improvement Act of 2026 Introduced
• Lawmakers introduce bipartisan bill to speed up MA prior authorization
• Health Care Week in Review | April 26, 2026 (Alston & Bird)
• Holland & Knight Health Dose: April 21, 2026
• AI Startup Has Helped Reverse Thousands of Denied Health Insurance Claims (Bloomberg)
• UnitedHealth Leaders Expect MA Costs Will Rise 10% in '26